India Moves On ……

A generic manufacturer spends virtually nothing on R&D, does not mean that without effort generics can be marketed. It actually requires the demonstration of safety and effect of the product by the innovator to the regulator for approval. The factors such as patent expirations on drugs, cost cutting measures on healthcare by US governments and the rising aging population in advanced countries and also the internal factors in India such as cost advantages in research, development and manufacture of drugs, well experience in reverse engineering of drugs, experience gained in the launch of generic products in less regulated markets and higher investment capital play major role in the sustained growth of the Indian generic players. Authorized generics, shared exclusivity, OTCs, more approval on day one and the larger size of the market are some attractive features of the US market, which makes every Indian generic company to be aggressive to step in the US market despite heavy launching